Volume 17 (2019): Issue 3.5 (Mar 2019): Abstracts from the NCCN 2019 Annual Conference

in Journal of the National Comprehensive Cancer Network
Online ISSN:
1540-1413
Print ISSN:
1540-1405
Cover Journal of the National Comprehensive Cancer Network
Young Investigator Awards
YIA19-001: Mechanisms of Diagnostic Delay Among Black women With Endometrial Cancer (EC): Results from Qualitative Interviews and a National Analysis of Healthcare Data
YIA19-002: Axl-RTK Inhibition Modulates T Cell Functions and Synergizes With Chimeric Antigen Receptor T Cell Therapy in B Cell Malignancies
YIA19-003: Size Matters: Larger Size CD19-Positive Extracellular Vesicles in Chronic Lymphocytic Leukemia (CLL) Inhibit Chimeric Antigen Receptor T-Cell Function
YIA19-004: Collateral Deletion of Glycolysis Genes Generates Selective Vulnerabilities to Inhibitors of Oxidative Phosphorylation
YIA19-005: Immunotherapy for Prostate Cancer Combining CAR-Engineered T Cells with Targeted Immune Checkpoint Inhibition
YIA19-007: Patient-Derived Tumor Organoids for Drug Discovery of High-Risk Hepatoblastoma
Best Practices in Implementation and Use of Clinical Practice Guidelines
BPI19-008: Racial Disparities in Breast Cancer Treatment Based on NCCN Quality Guidelines
BPI19-009: Late Administration of Luteinizing Hormone-Releasing Hormone (LHRH) Agonists and Testosterone Levels >50NG/DL in Prostate Cancer
BPI19-010: Febrile Neutropenia Induced by Chemotherapy: Impact of Risk Re-Stratification
BPI19-011: Assessment and Management of Older Patients With Metastatic Breast Cancer (MBC) Among Community Oncologists in the United States
BPI19-012: Differences in Stakeholder Perspectives Regarding Key Components of Shared Decision-Making for Mammography in Breast Cancer Screening for Women Ages 40–50
BPI19-013: Use of Clinical Decision Support and Peer Review to Increase NCCN Guidelines Adherence
BPI19-014: Standardization of a Survivorship Program: A Single Institution Experience
BPI19-015: Reduction of Inappropriate Prophylactic Pegylated Granulocyte Colony-Stimulating Factor (pGCSF) Use for Lung Cancer Patients: Five-Year Follow Up of a Quality Improvement (QI) Initiative at the Cleveland Clinic Taussig Cancer Institute (TCI)
BPI19-016: Evaluation of the Use of a Single Dose Rasburicase in Prophylaxis and Management of Tumor Lysis Syndrome (TLS) Among Cancer Patients in Qatar
BPI19-017: Clinical Pathway Toward Quality and Efficient Care of Breast Cancer in Women Under 50
BPI19-018: Cancer Screening Rates and Adherence of Uninsured Cancer Patients in Free Clinics
BPI19-019: Avoidable Acute Care Use Associated With Nausea and Vomiting Among Patients Receiving Highly Emetogenic Chemotherapy or Oxaliplatin
BPI19-020: A New Protecting Method for the Inferior Parathyroid Gland in situ: The Meticulous Thyrothymic Ligament Dissection Technique
BPI19-021: Medical Oncologist Perspectives of the Veterans Affairs National Precision Oncology Program
Bioinformatics/Information Technology Services
Clinical Oncology
CLO19-023: Induction Chemotherapy Followed by Chemoradiation and Trans-Anal Full Thickness Local Excision or Total Mesorectal Resection in Patients With T2-T3/NO-N+ Adenocarcinoma of the Rectum; Preliminary Results of Phase 2 Prospective Clinical Trial
CLO19-024: Risk of Atrial Fibrillation and Pulmonary Toxicities in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Treated With Ibrutinib
CLO19-025: Treatment Discontinuation Due to Adverse Events and the Risk of Gastrointestinal Toxicities in Patients With Hematologic Malignancies Treated With Ibrutinib
CLO19-026: Determining the Treatment Decision of Tumors With Mixed Response
CLO19-027: Assessment of Metastatic Invasive Lobular Carcinoma Management and Outcomes From 2004-2014: A Single Institution Experience
CLO19-028: Incidence and Management of Toxicities Associated With Anti-PD1 and Anti-PD-L1 Treatment Among Patients Enrolled in Medicare Advantage
CLO19-029: Dosing Patterns of Nilotinib Use in SIMPLICITY, an Observational Study in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients (Pts) in Routine Clinical Practice
CLO19-030: Duration of First Line Therapy in Metastatic Non-Small Cell Lung Cancer
CLO19-031: Immune Checkpoint Inhibitors: Optimization of Pharmacy Services in Toxicity Management
CLO19-033: Afatinib Followed by Osimertinib in EGFR Mutation-Positive (EGFRm+) Advanced NSCLC: Subgroup Analyses of the GioTag Study by ECOG PS, Age, and Ethnicity
CLO19-034: The Clinical Outcomes of Next-Generation Sequencing Testing at a Community Oncology Practice
CLO19-035: Safety Profile and Adverse Events of Sunitinib as a First-Line Treatment for Advanced/Metastatic Clear-Cell Renal Cell Carcinoma: Pooled Analysis of Randomized Controlled Trials
CLO19-036: Folate Receptor alpha Expression in Metastatic Triple-Negative Breast Cancer (TNBC)
CLO19-037: Reducing the Duration, Incidence and Severity of Mucosal Injury Due to Cancer Radiation therapy (RT); Positive Randomized Phase 2b Trial Results With GC4419 (Avasopasem Manganese), a Small Molecule Superoxide (SO) Dismutase (SOD) Mimetic
CLO19-040: The Role of Adjuvant Therapy in Patients With Pathological T2N0 Resected Gastric Adenocarcinoma
CLO19-041: Lymphatic Ligation Versus Conventional Axillary Lymph Node Dissection in Breast Cancer Patients: A Randomized Control Trial
CLO19-042: Quality Assurance for Cancer Radiotherapy: An Update on the Ottawa Hospital Peer Review Experience
CLO19-045: Safety of Immune Checkpoint Inhibitors in Cancer Patients With Microsatellite Instability-High (MSI-H) Status: An Experience From Qatar
CLO19-046: Follow-Up and Diagnosis of Breast Incidentalomas on Abdominal and Chest MRI
CLO19-047: Jeopardizing the Oncological Safety: Transurethral Resection of Bladder Tumor May Induce Measurable Hematogenous Seeding of Cancer Cells
CLO19-048: Effects of Acupuncture on Cutaneous Microcirculation by Infrared Thermography in Cancer Patients
CLO19-050: Risk of Health- Related Quality of Life (HRQOL) Events in Patients With Advanced Solid Tumors Treated With Cabozantinib: A Combined Analysis of Four Phase 3 Randomized Controlled Trials
CLO19-051: CDK 4/6 Inhibitor-Associated Hematologic Toxicities and Febrile Neutropenia in Patients With Hormone Receptor-Positive HER2-Negative Metastatic Breast Cancer
CLO19-052: Incidence of Ribociclib-Associated Cardiac Conduction Abnormalities in Patients With Hormone Receptor-Positive HER2-Negative Metastatic Breast Cancer: A Combined Analysis of 3 Phase III Randomized Controlled Trials
CLO19-053: Incidence of Cabozantinib-Associated Palmar-Plantar Erythrodysesthesia and Hypertension in Patients With Metastatic Solid Tumors: A Combined Analysis of 4 Phase III Randomized Controlled Trials
CLO19-054: Initial Experience of a Newly Set-up Robotic Assisted Radical Prostatectomy Program From a Developing Country—Delineating the Learning Curve
CLO19-055: Implementing Scalp Cooling: Considerations and Best Practice
CLO19-056: Scalp Cooling Proved to be Successful in the Prevention of Alopecia in >7,000 Patients With Solid Tumors
CLO19-058: Live Music to Decrease Patient Anxiety During Chemotherapy Treatments
CLO19-059: A Systematic Review and Meta- Analysis of Randomized Controlled Trials to Evaluate the Risk of Health-Related Quality of Life Events in Patients With Hormone Receptor-Positive HER2-Negative Metastatic Breast Cancer Treated With CDK 4/6 Inhibitors
CLO19-060: Blood Exosomal Long RNA Profiling Identifies Diagnostic and Prognostic Markers in Pancreatic Ductal Adenocarcinoma
Correlative/Genomic
Epidemiology/Risks
EPR19-066: Trends in Primary Squamous Cell Penile Cancer: A SEER Study
EPR19-067: Effectiveness of Breast Cancer Awareness Campaign on Internet Search Activity Compared to Other Gynecological Malignancies
EPR19-068: Association of Oral Premalignant Lesions with the Consumption of Tobacco
EPR19-069: Opioid Use Among Cancer Patients Undergoing Surgery and Their Associated Risk of Re-admissions and Emergency Department Visits in the 1-Year Postsurgical Period
EPR19-070: Incidence Pattern of Malignant Lymphoma by Cell-Lineage/Cell-Maturity Status in Nagasaki, Japan, 1985–2012: Preliminary Results
EPR19-071: Risk of Hematologic Toxicities and Health-Related Quality of Life Events in Patients With Hematologic Malignancies Treated With Ibrutinib: A Combined Analysis of 6 Phase III Trials
EPR19-072: Breast Cancer Laterality and Immunohistochemical Characteristics
EPR19-73: Risk of Gastrointestinal and Hepatic Toxicities in Patients With Hormone Receptor-Positive HER2-Negative Metastatic Breast Cancer Treated With CDK4/6 Inhibitors
EPR19-74: Risk of Cabozantinib-Associated Gastrointestinal and Hepatic Toxicities in Patients With Metastatic Solid Tumors: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
EPR19-075: Geographic Region and Race/Ethnicity Are Associated With Treatment and Survival for Gastric Cancer
Outcomes and Health Services Research
HSR19-076: A Prospective Study of the Usage of Pain Medication, Cost, Alternative Medication Use, and Outcome by Cancer Patients in Real World
HSR19-077: Primary Tumor Location (PTL) and Survival Outcomes in a Real World Cohort of KRAS Wild-Type (WT) Metastatic Colorectal Cancer (mCRC) Patients in the United States
HSR19-078: Human Papillomavirus Status and Survival Among Patients With Oropharyngeal Cancer: Analyses of a United States Health System
HSR19-079: Disparities in Accessing Screening Mammography: Opportunities for Improving Diagnostic Outcomes
HSR19-080: Situational Analysis and Needs Assessment Regarding the Availability and Extent of Pediatric Palliative Care Services in the Philippines
HSR19-082: Epidemiological Findings and Outcomes in Non-Small Cell Lung Cancer Patients with Exon 20 Insertion Mutations: A Meta-Analysis
HSR19-083: Treatment Heterogeneity and Overall Survival (OS) in Patients With Advanced/Metastatic Gastric/Gastroesophageal Junction Cancer (aGC/GEJ) in the United States
HSR19-084: Real-World Treatment Patterns and Clinical Outcomes in Non-Small Cell Lung Cancer Patients with EGFR Exon 20 Insertion Mutations
HSR19-085: A Real World Observational Assessment of the Impact of Immunotherapy on the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)
HSR19-086: Healthcare Costs and Resource Utilization Associated With Adverse Events Among Hairy Cell Leukemia Patients Treated With Purine Nucleoside Analogs
HSR19-087: Intensity of Symptom Management After Palliative Care Referral Not Associated With Reduced Imaging Intensity for Cancer Patients During the End-of-Life Period
HSR19-088: Severe Obesity Does Not Worsen Transplantation Outcome in Multiple Myeloma
HSR19-089: Misperceptions Regarding Palliative and Hospice Care Among Cancer Patients: What Can We Learn from Patient-Reported Treatment Decision Making
HSR19-090: Changes in Adherence to Tyrosine Kinase Inhibitor Treatment Patterns Among Patients With Chronic Myeloid Leukemia and the Impact on Costs: 2001–2017
HSR19-091: Incidence of Adverse Events Following Use of Different PARP Inhibitors: Systematic Review and Meta-Analysis
HSR19-092: Adjuvant Radiotherapy Is Associated with Improved Overall Survival for Resected Alveolar Ridge Squamous Cell Carcinoma With Adverse Pathologic Features
HSR19-094: A Comparison of Cancer Burden and Funding From the National Cancer Institute and Nonprofit Organizations Reveals Disparities in the Distribution of Funding Across Cancer Types
HSR19-095: Healthcare Resource Utilization and Costs in Patients Treated with Systemic Therapies in Metastatic Melanoma
HSR19-096: The Impact of New Oncology Drugs on Disability and Health Care Spending: An Assessment of Real-World Evidence
HSR19-097: Understanding U.S. Mutational Testing Patterns and Treatment Implications in Gastrointestinal Stromal Tumors (GIST) Patients
HSR19-099: Harnessing the Voice of Patients With Genetic Mutations in NSCLC Treatment
HSR19-100: CancerSupportSource®-15: Development and Evaluation of a Short Form of a Distress Screening Program for Cancer Survivors
HSR19-102: Direct and Indirect Economic Burden of Cervical Cancer (CxCa) in the United States in 2015: A Mixed-Methods Analysis
HSR19-103: Burden of Self-Reported Mental Health Among Women With Cervical Cancer (CC) in the United States
HSR19-104: Patterns of Providers’ Mammogram Referrals for Asymptomatic Breast Cancer Survivors
HSR19-105: The Role of Chemotherapy in Elderly Colorectal Cancer Survivors: An Observational Study
HSR19-106: Association Between Pathological Complete Responses and Long-Term Survival Outcomes Among Triple-Negative Breast Cancer Patients Receiving Neoadjuvant Chemotherapy
HSR19-107: Nivolumab for Newly Diagnosed Classical Hodgkin Lymphoma: Patient-Reported Outcomes From CheckMate 205 Cohort D
HSR19-108: A Meta-Analysis of Randomized Controlled Trials (RCTs) for Efficacy and Safety of Vascular Endothelial Growth Factor Tyrosine Kinase Inhibitors (VEGF-TKIs) Adjuvant Therapy in High-Risk Renal Cell Cancer (RCC)
HSR19-109: The Healthy Days Measure in a Metastatic Castration-Resistant Prostate Cancer Population Treated With Novel Oral Therapies
HSR19-110: Predicting Candidates for Cytoreductive Surgery and HIPEC: The Role of Computed Tomography and Diagnostic Laparoscopy
HSR19-111: Disparities in Guideline-Concordant Care Among HER2 Positive Metastatic Breast Cancer Patients
HSR19-112: Qualitative Development of a Patient-Reported Outcome Measure of Symptom Burden in Breast Cancer
HSR19-113: Valued Outcomes in the Cancer Experience (VOICE™): Scale Development and Initial Validation
Pre-Clinical Oncology
Quality Improvement
QIM19-115: Barriers and Trends in Cancer Patients` Pain Management in Qatar: A Randomized Cohort Prospective Study
QIM19-116: Barriers and Trends in Cancer Patients’ referrals to Pain Management in Qatar: A Randomized Cohort Prospective Study
QIM19-117: Reducing Diagnostic Delays: Impact of a Novel Cancer Diagnostic Service
QIM19-118: Oral Anti-Cancer Therapy Initiation: A Standardized Approach for Patient Care and Education
QIM19-119: Validity of the French-Language Mammography Satisfaction Instrument Evaluating Women’s Satisfaction With an Organized Breast Cancer Screening Program: A Confirmatory Study
QIM119-120: Utilizing Technology to Identify Oncology Patients to Impact Patient Care
QIM19-121: Improving Testing for Hepatitis B Before Treatment With Rituximab Through Automated Electronic Health Record Alert System: A Single Institutional Retrospective Review and Quality Improvement Project
QIM19-122: Quality Improvement Initiatives in the Second Year of an Adolescent and Young Adult Oncology Clinic
QIM19-123: Addressing Opportunities for Improving Care Cadence by Driving Interdepartmental Collaboration
QIM19-124: Does Virtual Navigation Improve Care Continuity and Compliance in Patients With Early Stage Colon Cancer?
QIM19-125: Nonclinical Needs of Cancer Patients in Spain Under Different Perspectives: A Comparative Study
QIM19-126: NCCN Member Institution Patient Education and Teaching for Biliary Stents and Drains
QIM19-127: Novel Admission Checklist for Malignant Bowel Obstruction
QIM19-128: Improving Oral Chemotherapy Safety in Adult Neuro-Oncology Clinics
QIM19-129: Utilization of Electronic Medical Record to Improve Outcomes in the Treatment of Febrile Neutropenia
QIM19-130: Quality Improvement Project to Standardize a Prehabilitation Pathway for Patients With Esophageal Cancer Receiving Neoadjuvant Chemoradiation
QIM19-132: Trastuzumab Induced Cardiotoxicity: Are We Monitoring and Managing Appropriately?
QIM19-133: Assessing and Reducing FDG PET/CT Radiotracer Infiltrations: Lessons in Quality Improvement Sustainability
QIM19-134: Improving Access to Bone Marrow Transplant in the Community: The Memorial Sloan Kettering Cancer Alliance Shared Care Program
QIM19-135: The Quality Oncology Practice Initiative Program: Experience in Spain
QIM19-136: Developing an Ideal CAR-T Cell Therapy Patient Experience Through Human-Centered Design and Innovation
QIM19-137: Effect of Socioeconomic Factors on Survival in Veterans With Acute Myeloid Leukemia
QIM19-138: Care Coordination Between Prescribers and the Specialty Pharmacy—Qualitative Insights Into Designing a Quality Improvement Program for Multisite Community Oncology Practices
QIM19-139: Reflex Testing of Oncotype DX Recurrence Score: A Single Institution Review of a Quality Improvement Protocol
QIM19-140: A New Standard of Care
QIM19-141: SOAR (Survivors Overcoming and Achieving Resilience)
QIM19-142: Development of a Low Resource Tool for Improving Head and Neck Cancer Treatment Delivery Within an Integrated Health Care Delivery System
QIM19-143: Reducing Risk of IV Chemotherapy Administration Errors Utilizing Pump Integration Technology
QIM19-144: Health-Related Quality of Life and Stress Level in Patients After Thyroid Resection Due to Cancer Depends on Patients’ Knowledge About Their Disease and Treatment Plan: Preliminary Results
QIM19-145: Overcoming a Barrier to Exercise With the James Exercise Program Quality Initiative With Surgical Oncology Nursing
QIM19-146: A Multidisciplinary Approach to Conquer Central-Line Associated Blood Stream Infections: Establishing the Continuum of Prevention
  • Collapse
  • Expand